NasVax Finalizes Share Purchase Agreement with Protea Vaccine Technologies
NasVax Ltd. announced that it has signed an agreement with Protea Vaccine Technologies Ltd (Protea) to purchase all of the company's shares.
Protea is developing an innovative next-generation vaccine against diseases caused by Streptococcus pneumoniae, based on widely conserved pneumococcal proteins. Pneumococcal vaccine is one of the two largest market segments in prophylactic vaccines. Sales of $2.5B for pneumococcal vaccines in 2007 are growing at an annual rate of >30%.
Erez Chimovits, CEO of NasVax, says: “This deal is a very significant step in our strategy. It enables us to become an integrated vaccine company that, in addition to having a proprietary technology for improving vaccines, would enter one of the most attractive fields in the world of prophylactic vaccines, and with the potential for combining NasVax’s innovative technology with that of Protea.”
Protea has grown within Meytav, in which NasVax also was established, on the basis of technology developed in the laboratories in Israel of Professor Yaffa Mizrachi-Nebenzahl, who is a member of the Children’s Infectious Disease Unit in the Microbiology & Immunology Departments in the Faculty of Health Sciences in Ben Gurion University, and Professor Ron Dagan, who is Head of the Children’s Infectious Disease Unit in Soroka University Hospital and who has a worldwide reputation in the fields of pediatric vaccines and pneumococcal infections.
Other news from the department business & finance
These products might interest you
Systec H-Series by Systec
Safe, reproducible and validatable sterilization of liquids, solids and waste
Autoclaves with 65-1580 liters usable space, flexibly expandable for various applications
Whatman™ folded filter papers by Cytiva
Whatman folded filter papers
Convenient folded formats speed up your sample preparation
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
